```html

Hemangioma – Comprehensive Medical Guide

Overview

A hemangioma is a benign (non‑cancerous) tumor made up of blood vessels. Most commonly it appears as a raised, bright‑red or bluish birthmark on the skin, but it can also develop internally (e.g., in the liver, brain, or larynx). Hemangiomas are the most frequent type of vascular tumor in infants, occurring in about 5–10 % of newborns worldwide.

While the majority of hemangiomas appear in the first few weeks of life and then gradually shrink (a process called involution), a small proportion persist into adulthood or cause functional problems that require treatment.

Typical Age of Onset	Birth to 4 weeks
Gender Predilection	More common in females (≈3:1 female‑to‑male ratio)
Ethnicity	Higher incidence in Caucasians and Asian populations; lower in African‑American infants

Symptoms

Symptoms vary widely depending on the size, depth, and location of the hemangioma. Below is a complete list of common presentations.

Cutaneous (Skin) Hemangiomas

• Bright red “strawberry” plaque – raised, smooth surface, usually on the face, scalp, or neck.
• Deep or “cavernous” hemangioma – bluish, compressible mass; often found on trunk or extremities.
• Mixed lesions – combination of superficial and deep components.
• Rapid growth phase – enlarges quickly over the first 6–12 months of life.
• Ulceration – painful open sores, more common on areas subject to friction (e.g., diaper area).
• Bleeding – may occur after minor trauma or during ulceration.

Internal Hemangiomas

• Liver (hepatic) hemangioma – abdominal fullness, right‑upper‑quadrant pain, or incidental finding on imaging.
• Airway hemangioma – stridor, noisy breathing, feeding difficulties in infants.
• Orbital hemangioma – protruding eye (proptosis), vision changes, or amblyopia.
• Spinal cord hemangioma – back pain, weakness, or neurologic deficits (rare).

Causes and Risk Factors

The exact cause of hemangiomas remains unknown, but research points to a combination of genetic, cellular, and environmental factors.

• Early‑life angiogenic signaling – abnormal proliferation of endothelial cells (the cells that line blood vessels) during the first weeks after birth.
• Genetic predisposition – families with multiple affected members suggest a possible hereditary component, though no single gene has been definitively identified.
• Prematurity and low birth weight – infants born before 37 weeks or weighing <2,500 g have a 2–3‑fold higher risk (CDC, 2022).
• Female sex – hormones may play a role; estrogen receptors have been found in some hemangioma tissue.
• Placental abnormalities – conditions like maternal hypertension or placental insufficiency are associated with higher incidence.

Diagnosis

Diagnosing a hemangioma usually begins with a thorough clinical examination. Most superficial lesions can be identified by sight and feel alone. When the appearance is atypical or the lesion is internal, additional tests are employed.

Clinical Evaluation

• History: onset, growth pattern, symptoms (pain, ulceration, bleeding).
• Physical exam: size, color, depth, and involvement of surrounding structures.

Imaging Studies

• Ultrasound with Doppler – first‑line for superficial and many deep lesions; shows blood flow patterns.
• Magnetic Resonance Imaging (MRI) – provides detailed anatomy, especially for facial, orbital, or spinal lesions.
• Computed Tomography (CT) scan – useful for hepatic hemangiomas or when MRI is contraindicated.
• Angiography – rarely needed, reserved for complex vascular lesions requiring embolization.

Laboratory Tests

Blood work is not typically required for diagnosis, but the following may be ordered if complications are suspected:

• Complete blood count (CBC) – to assess anemia from chronic bleeding.
• Liver function tests – for large hepatic hemangiomas.
• Coagulation profile – if there is unexplained bruising or bleeding.

Treatment Options

Because most infantile hemangiomas involute spontaneously, observation is often the first step. Treatment is considered when lesions threaten vision, breathing, hearing, cause ulceration, or result in significant cosmetic concerns.

Medications

• Propranolol (beta‑blocker) – First‑line oral therapy; 2–3 mg/kg/day given in divided doses. Reduces size in ~90 % of treated infants (Mayo Clinic, 2023).
< Timolol (topical beta‑blocker) – Applied 0.5 % solution to superficial lesions; safe for small facial hemangiomas.
• Corticosteroids – Oral or intralesional; historically used but now secondary to propranolol due to side‑effect profile.
• Sirolimus (mTOR inhibitor) – For complicated, refractory hemangiomas, especially those involving the airway or visceral organs.

Procedural Interventions

• Laser therapy (pulsed dye laser) – Effective for superficial, ulcerated, or residual reddish tissue after involution.
• Intralesional injection of steroids or bleomycin – Reserved for lesions that do not respond to oral medication.
• Embolization – Targeted blockage of feeding vessels for large hepatic or high‑flow lesions.
• Surgical excision – Considered when the lesion is well‑defined, causing functional impairment, or after involution leaves excess tissue.

Lifestyle & Supportive Care

• Gentle skin care – keep ulcerated lesions clean, use barrier creams.
• Protective padding – for lesions in areas prone to friction (e.g., diaper rash).
• Regular monitoring – chart growth weekly during the proliferative phase.
• Parental education – reassure that most lesions improve on their own.

Living with Hemangioma

Whether you are caring for an infant or managing an adult lesion, practical day‑to‑day strategies can improve comfort and outcomes.

• Sun protection – Use broad‑spectrum sunscreen (SPF 30+) on exposed lesions to prevent irritation and hyperpigmentation.
• Temperature regulation – Excess heat can cause rapid expansion; keep the child in a cool environment during hot weather.
• Gentle washing – Use mild, fragrance‑free cleansers; avoid scrubbing.
• Follow‑up schedule – Most pediatric dermatologists recommend visits every 2–4 weeks during growth, then every 3–6 months as the lesion involutes.
• Psychosocial support – Visible facial hemangiomas can affect self‑esteem; counseling or support groups are beneficial.

Prevention

Because the precise cause is unknown, specific primary prevention is limited. However, some measures may lower risk or severity:

• Maintain a healthy pregnancy – adequate prenatal care, control of maternal hypertension, and avoidance of smoking.
• Targeted monitoring for premature infants – early dermatologic evaluation for high‑risk newborns.
• Educate caregivers on gentle handling to avoid trauma that could exacerbate ulceration.

Complications

While most hemangiomas are harmless, complications can arise, especially when lesions are large, deep, or located near vital structures.

• Ulceration and infection – Painful open sores can become secondarily infected.
• Bleeding – Particularly with ulcerated or traumatized lesions.
• Vision loss – Orbital hemangiomas may cause amblyopia if untreated.
• Airway obstruction – Subglottic hemangiomas can lead to stridor or respiratory failure.
• High‑output cardiac failure – Very large hepatic hemangiomas may shunt enough blood to strain the heart.
• Scarring or disfigurement – Residual tissue after involution may require cosmetic surgery.

When to Seek Emergency Care

References

• Mayo Clinic. “Hemangioma.” 2023. https://www.mayoclinic.org
• Centers for Disease Control and Prevention (CDC). “Birth Defects and Prematurity.” 2022.
• National Institutes of Health (NIH). “Vascular Anomalies.” 2021.
• Cleveland Clinic. “Infantile Hemangioma Treatment.” 2022.
• World Health Organization (WHO). “International Classification of Diseases – Vascular Tumors.” 2020.
• Huang S, et al. “Propranolol for Infantile Hemangioma: A Systematic Review.” *JAMA Dermatology*, 2022.

```